Total Payments
$23,744
2024 Payments
$3,253
Companies
86
Transactions
1,122
Medicare Patients
8,369
Medicare Billing
$2.5M
Payment Breakdown by Category
Food & Beverage$18,666 (78.6%)
Research$3,811 (16.1%)
Education$1,267 (5.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $18,666 | 1,090 | 78.6% |
| Unspecified | $3,811 | 2 | 16.1% |
| Education | $1,267 | 30 | 5.3% |
Payments by Type
General
$19,933
1,120 transactions
Research
$3,811
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $3,811 | 2 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $1,489 | 105 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,093 | 64 | $0 (2024) |
| PFIZER INC. | $1,057 | 74 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $987.11 | 61 | $0 (2024) |
| Genentech USA, Inc. | $893.91 | 68 | $0 (2024) |
| Amgen Inc. | $808.15 | 46 | $0 (2023) |
| Celgene Corporation | $771.17 | 46 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $688.94 | 43 | $0 (2024) |
| Janssen Biotech, Inc. | $681.37 | 47 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,253 | 142 | Novartis Pharmaceuticals Corporation ($214.06) |
| 2023 | $3,066 | 140 | Gilead Sciences, Inc. ($264.41) |
| 2022 | $6,667 | 150 | Eli Lilly and Company ($3,811) |
| 2021 | $1,418 | 76 | Janssen Biotech, Inc. ($137.79) |
| 2020 | $912.15 | 51 | Myriad Genetic Laboratories, Inc. ($67.94) |
| 2019 | $2,949 | 185 | PFIZER INC. ($207.27) |
| 2018 | $2,926 | 186 | PFIZER INC. ($295.25) |
| 2017 | $2,553 | 192 | Novartis Pharmaceuticals Corporation ($387.82) |
All Payment Transactions
1,122 individual payment records from CMS Open Payments — Page 1 of 45
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/27/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $18.41 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $13.73 | General |
| Category: Oncology | ||||||
| 12/18/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $29.67 | General |
| Category: Hematology | ||||||
| 12/13/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $27.78 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $36.49 | General |
| Category: Oncology | ||||||
| 12/11/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $18.11 | General |
| Category: DESMOID TUMORS | ||||||
| 12/10/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $24.58 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Somatuline Depot | Food and Beverage | In-kind items and services | $18.15 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $15.11 | General |
| Category: Oncology | ||||||
| 11/27/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $14.49 | General |
| 11/27/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $13.65 | General |
| Category: ONCOLOGY | ||||||
| 11/22/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $19.49 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/21/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $21.58 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $13.47 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $22.63 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $15.85 | General |
| Category: Hematology | ||||||
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $21.07 | General |
| Category: Oncology | ||||||
| 11/08/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $22.85 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $25.86 | General |
| Category: Oncology | ||||||
| 10/30/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $22.23 | General |
| Category: Hematology/Oncology | ||||||
| 10/29/2024 | Genentech USA, Inc. | Itovebi (Biological), Phesgo | Food and Beverage | In-kind items and services | $15.52 | General |
| Category: BioOncology | ||||||
| 10/23/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $25.35 | General |
| Category: ONCOLOGY | ||||||
| 10/22/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $20.52 | General |
| 10/21/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $20.08 | General |
| Category: Immunology | ||||||
| 10/17/2024 | Takeda Pharmaceuticals U.S.A., Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $24.85 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| POSTMONARCH: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS FULVESTRANT TO PLACEBO PLUS FULVESTRANT IN PARTICIPANTS WITH HR+, HER2-, ADVANCED OR METASTATIC BREAST CANCER FOLLOWING PROGRESSION ON A CDK4 & 6 INHIBITOR AND ENDOCRINE THERAPY | Eli Lilly and Company | $2,513 | 1 |
| CYCLONE 3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ABEMACICLIB IN COMBINATION WITH ABIRATERONE PLUS PREDNISONE IN MEN WITH HIGH-RISK METASTATIC HORMONE-SENSITIVE PROSTATE CANCER | Eli Lilly and Company | $1,298 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 40 | 2,168 | 64,125 | $1.8M | $405,945 |
| 2022 | 38 | 1,911 | 68,269 | $3.1M | $757,528 |
| 2021 | 37 | 2,268 | 77,147 | $2.8M | $855,914 |
| 2020 | 34 | 2,022 | 60,494 | $1.6M | $457,329 |
Total Patients
8,369
Total Services
270,035
Medicare Billing
$2.5M
Procedure Codes
149
All Medicare Procedures & Services
149 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 22 | 6,120 | $391,680 | $113,526 | 29.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 344 | 1,090 | $425,100 | $95,065 | 22.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 67 | 347 | $146,087 | $30,929 | 21.2% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 17 | 1,700 | $125,800 | $27,591 | 21.9% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 44 | 206 | $43,260 | $14,925 | 34.5% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 27 | 36,210 | $144,840 | $14,242 | 9.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 479 | 1,689 | $48,981 | $12,763 | 26.1% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 18 | 8,970 | $53,820 | $12,296 | 22.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 36 | 114 | $35,112 | $10,353 | 29.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 129 | 157 | $43,489 | $9,357 | 21.5% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 22 | 163 | $38,142 | $8,185 | 21.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 48 | 48 | $24,432 | $5,278 | 21.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 43 | 117 | $24,336 | $5,131 | 21.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 62 | 450 | $29,700 | $4,966 | 16.7% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 24 | 85 | $17,425 | $3,835 | 22.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 23 | 27 | $16,065 | $3,530 | 22.0% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 52 | 136 | $16,456 | $3,516 | 21.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 220 | 409 | $3,681 | $3,419 | 92.9% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2023 | 19 | 25 | $13,575 | $3,073 | 22.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 18 | 18 | $12,114 | $2,979 | 24.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 18 | 49 | $10,486 | $2,920 | 27.9% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 23 | 138 | $14,214 | $2,838 | 20.0% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 11 | 65 | $11,505 | $2,557 | 22.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 18 | 19 | $10,450 | $2,325 | 22.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 52 | 208 | $13,936 | $2,072 | 14.9% |
About Dr. Christopher Mccanless, MD
Dr. Christopher Mccanless, MD is a Medical Oncology healthcare provider based in Baton Rouge, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1013995646.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Mccanless, MD has received a total of $23,744 in payments from pharmaceutical and medical device companies, with $3,253 received in 2024. These payments were reported across 1,122 transactions from 86 companies. The most common payment nature is "Food and Beverage" ($18,666).
As a Medicare-enrolled provider, Mccanless has provided services to 8,369 Medicare beneficiaries, totaling 270,035 services with total Medicare billing of $2.5M. Data is available for 4 years (2020–2023), covering 149 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Hematology & Oncology
- Location Baton Rouge, LA
- Active Since 01/04/2006
- Last Updated 10/03/2024
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1013995646
Products in Payments
- KEYTRUDA (Biological) $1,065
- OPDIVO (Biological) $662.48
- JEVTANA (Drug) $558.31
- IBRANCE (Drug) $449.09
- IMBRUVICA (Drug) $436.29
- BRUKINSA (Drug) $408.31
- XTANDI (Drug) $346.13
- KISQALI (Drug) $339.66
- Trodelvy (Drug) $332.99
- Imbruvica (Drug) $300.70
- NINLARO (Drug) $294.28
- Revlimid (Drug) $282.10
- LYNPARZA (Drug) $275.59
- Stivarga (Drug) $250.32
- LIBTAYO (Biological) $249.13
- VERZENIO (Drug) $248.10
- Nplate (Biological) $243.00
- TASIGNA (Drug) $233.34
- Enhertu (Drug) $222.26
- CYRAMZA (Drug) $220.23
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Baton Rouge
Dr. Michael Castine, Md, MD
Medical Oncology — Payments: $332,086
Medical Oncology $332,086
Lauren Juneja, Md, MD
Medical Oncology — Payments: $13,511
Medical Oncology $13,511
Cody Milliman
Medical Oncology — Payments: $4,226
Medical Oncology $4,226
Mr. William Varnado
Medical Oncology — Payments: $4,103
Medical Oncology $4,103